Axon Enterprise, Inc. (NASDAQ:AXON) Receives Average Recommendation of “Moderate Buy” from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has been assigned an average rating of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $365.38.

Several analysts recently commented on the company. Robert W. Baird raised their price objective on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Northland Securities increased their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Bank of America started coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Jefferies Financial Group started coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Finally, Craig Hallum increased their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th.

Insider Activity

In related news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Jeri Williams sold 110 shares of Axon Enterprise stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the transaction, the director now owns 1,934 shares in the company, valued at approximately $773,600. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at $1,121,052,771.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock worth $137,000,162 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds have recently bought and sold shares of the stock. Avantax Advisory Services Inc. lifted its position in Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after acquiring an additional 40 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Axon Enterprise during the first quarter worth approximately $931,000. Zurich Insurance Group Ltd FI lifted its position in Axon Enterprise by 1.9% during the second quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock worth $60,324,000 after acquiring an additional 3,832 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Axon Enterprise by 14.8% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock valued at $53,307,000 after buying an additional 22,013 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Axon Enterprise by 21.7% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after buying an additional 1,634 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $433.83 on Thursday. The company has a market capitalization of $32.74 billion, a PE ratio of 126.85, a PEG ratio of 11.49 and a beta of 0.94. Axon Enterprise has a 12 month low of $199.29 and a 12 month high of $440.89. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock’s fifty day simple moving average is $385.93 and its 200 day simple moving average is $330.03.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s revenue was up 34.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 EPS. On average, research analysts predict that Axon Enterprise will post 1.79 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.